# US 2003/0216387 A1 · Materials and methods for the treatment of gastroesophageal reflux disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216387 A1
- Document ID: US20030216387A1
- Status: Published application
- Kind: A1
- Application number: 10/418,842
- Filed: 2003-04-18
- Published: 2003-11-20
- Earliest claimed: 2000-06-07
- Inventors: Pascal Druzgala; Peter G. Milner; Jurg Pfister; Cyrus Becker
- Web page: https://patentgrep.com/patent/US20030216387A1

## CPC

- C07D 211/58: attached in position 4
- A61K 31/4468: having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 1/14: Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A61P 9/12: Antihypertensives
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 211/46: having a hydrogen atom as the second substituent in position 4
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The subject invention provides novel compounds and compositions for the safe and effective treatment of gastroesophageal reflux and related conditions. In a preferred embodiment, the compositions of the subject invention comprise esterified cisapride derivatives. These compositions possess potent activity in treating gastroesophageal reflux disease and substantially reduce adverse effects associated with the administration of cisapride. These adverse effects include, but are not limited to, diarrhea, abdominal cramping and elevations of blood pressure and heart rate.

## Claims

### Claim 1

A method for treating a disease state which can be improved by stimulating the motility of the gastrointestinal system wherein said method comprises administering, to an individual in need of such a treatment, a compound, or an analog or salt thereof, wherein said compound has the following structure:
14
wherein:
R1 is H, C1-4 alkyl, OH, OC1-4alkyl, —COOH, —COOC1-4alkyl, —O(C═O)OC1-4alkyl, —O(C═O)C1-4alkyl, or —C1-4alkylNR7R8 where R7 and R9 are, independently, H or C1-4 alkyl;
R2 is H, C1-4 alkyl, —OC1-4alkyl, —COOH, or —(C═O)OC1-4alkyl;
X is O or N;
R3 is H or C1-3 alkyl (if X is an oxygen atom, then R3 does not exist);
R4, R5, and R6 are each, independently, selected from the group consisting of hydrogen, C1-4 alkyl, —OC1-4alkyl, halogen atom, hydroxy, cyano, nitro, amino, mono- and di(lower alkyl)amino, aminocarbonyl, arylcarbonylamino, alkylcarbonylamino, lower-alkyl carbonyl, lower-alkyl carbonyloxy, aminosulfonyl, lower-alkylsulfinyl, lower-alkylsulfonyl, lower-alkylthio and mercapto; and
wherein L has the formula —CnH2n—X—CmH2m—(CR9R10)p—(C═O)O—Y, wherein
n is an integer from 1 to 4 inclusive;
X is —CH(OH)—, —NH—, —S—, —O—, or a direct bond;
m is an integer from 0 to 4 inclusive;
p is 0 or 1;
R9 and R10 are, independently, H, C1-4 alkyl, or R9R10 are linked and together form a 5- or a 6-membered cycloalkyl ring; and
Y is H, C1-4 alkyl or cycloalkyl optionally substituted by 1 or more heteroatoms selected from the group consisting of O; N; S; or aryl or heteroaryl optionally substituted by 1 or more halogen atoms, C1-4 alkyl, C1-4alkoxy, hydroxy, cyano, amino, alkylamino, dialkylamino, trifluoromethyl, —COOH, or —COOC1-4alkyl.

### Claim 2 (depends on 1)

The method, according to claim 1, wherein said disease state is selected from the group consisting of gastroesophageal reflux disease, dyspepsia, gastroparesis, constipation, post-operative ileus, and intestinal pseudo-obstruction.

### Claim 3 (depends on 2)

The method, according to claim 2, wherein said disease state is gastroesophageal reflux disease.

### Claim 4 (depends on 1)

The method, according to claim 1, wherein said individual is a human.

### Claim 5 (depends on 1)

The method, according to claim 1, wherein R4, R5, and R6 are, independently, selected from the group consisting of halo, amino, mono- and dialkylamino, and lower alkyloxy.

### Claim 6 (depends on 1)

The method, according to claim 1, wherein R4 is methoxy, R5 is amino or methylamino, and R6 is chloro, in the 2-, 4-, and 5-position of the phenyl ring, respectively.

### Claim 7 (depends on 1)

The method, according to claim 1, wherein said compound is selected from the group consisting of:
15
where IIIa and IIIb are mirror images of each other (enantiomers), and where L is defined as shown in Formula (II):
16
where n—1 to 4, m—O to 4, X is a direct bond and Y is hydrogen, lower alkyl, or substituted aryl.

### Claim 8 (depends on 1)

The method, according to claim 1, wherein R1═OCH3; R2—H; X═O or N (if X═N, then R3═H); R4, R5, and R6 are methoxy, amino, and chlorine at the 2, 4, and 5-position of the phenyl ring, respectively.

### Claim 9 (depends on 1)

The method, according to claim 1, wherein both asymmetric centers are in the cis-configuration.

### Claim 10

A compound, or an analog or salt thereof, wherein said compound has the following structure:
17
wherein:
R1 is H, C1-4 alkyl, OH, OC1-4alkyl, —COOH, —COOC1-4alkyl, —O(C═O)OC1-4alkyl, —O(C═O)C1-4alkyl, or —C1-4alkylNR7R8 where R7 and R8 are, independently, H or C1-4 alkyl;
R2 is H, C1-4 alkyl, —OC1-4alkyl, —COOH, or —(C═O)OC1-4alkyl;
X is O or N;
R3 is H or C1-3 alkyl (if X is an oxygen atom, then R3 does not exist);
R4, R5, and R6 are each, independently, selected from the group consisting of hydrogen, C1-4 alkyl, —OC1-4alkyl, halogen atom, hydroxy, cyano, nitro, amino, mono- and di(lower alkyl)amino, aminocarbonyl, arylcarbonylamino, alkylcarbonylamino, lower-alkyl carbonyl, lower-alkyl carbonyloxy, aminosulfonyl, lower-alkylsulfinyl, lower-alkylsulfonyl, lower-alkylthio and mercapto; and
wherein L has the formula —CnH2n—X—CmH2m—(CR9R10)p—(C═O)O—Y, wherein
n is an integer from 1 to 4 inclusive;
X is —CH(OH)—, —NH—, —S—, —O—, or a direct bond;
m is an integer from 0 to 4 inclusive;
p is 0 or 1;
R9 and R10 are, independently, H, C1-4 alkyl, or R9R10 are linked and together form a 5- or a 6-membered cycloalkyl ring; and
Y is H, C1-4 alkyl or cycloalkyl optionally substituted by 1 or more heteroatoms selected from the group consisting of O; N; S; or aryl or heteroaryl optionally substituted by 1 or more halogen atoms, C1-4 alkyl, C1-4alkoxy, hydroxy, cyano, amino, alkylamino, dialkylamino, trifluoromethyl, —COOH, or —COOC1-4alkyl.

### Claim 11

A method for treating a condition which is susceptible to treatment by modulation of serotonergic systems wherein said method comprises administering to an individual in need of such treatment, an effective amount of a compound, or an analog or salt thereof, wherein said compound has the following structure:
18
wherein:
R1 is H, C1-4 alkyl, OH, OC1-4alkyl, —COOH, —COOC1-4alkyl, —O(C═O)OC1-4alkyl, —O(C═O)C1-4alkyl, or —C1-4alkylNR7R8 where R7 and R8 are, independently, H or C1-4 alkyl;
R2 is H, C1-4 alkyl, —OC1-4alkyl, —COOH, or —(C═O)OC4alkyl;
X is O or N;
R3 is H or C1-3 alkyl (if X is an oxygen atom, then R3 does not exist);
R4, R5, and R6 are each, independently, selected from the group consisting of hydrogen, C1-4 alkyl, —OC1-4alkyl, halogen atom, hydroxy, cyano, nitro, amino, mono- and di(lower alkyl)amino, aminocarbonyl, arylcarbonylamino, alkylcarbonylamino, lower-alkyl carbonyl, lower-alkyl carbonyloxy, aminosulfonyl, lower-alkylsulfinyl, lower-alkylsulfonyl, lower-alkylthio and mercapto; and
wherein L has the formula —CnH2n—X—CmH2m—(CR9R10)p—(C═O)O—Y, wherein
n is an integer from 1 to 4 inclusive;
X is —CH(OH)—, —NH—, —S—, —O—, or a direct bond;
m is an integer from 0 to 4 inclusive;
p is 0 or 1;
R9 and R10 are, independently, H, C1-4 alkyl, or R9R10 are linked and together form a 5- or a 6-membered cycloalkyl ring; and
Y is H, C1-4 alkyl or cycloalkyl optionally substituted by 1 or more heteroatoms selected from the group consisting of O; N; S; or aryl or heteroaryl optionally substituted by 1 or more halogen atoms, C1-4 alkyl, C1-4alkoxy, hydroxy, cyano, amino, alkylamino, dialkylamino, trifluoromethyl, —COOH, or —COOC1-4alkyl.

### Claim 12 (depends on 11)

The method, according to claim 11, wherein said condition is selected from the group consisting of 1) cognitive disorders, 2) behavioral disorders, 3) mood disorders, and 4) disorders of control of autonomic function.

### Claim 13 (depends on 12)

The method, according to claim 12, wherein said cognitive disorder is Alzheimer's disease.

### Claim 14 (depends on 12)

The method, according to claim 12, wherein said behavioral disorder is selected from the group consisting of schizophrenia, mania, obsessive-compulsive disorder, and psychoactive substance use disorders.

### Claim 15 (depends on 12)

The method, according to claim 12, wherein said mood disorder is selected from the group consisting of depression and anxiety.

### Claim 16 (depends on 12)

The method, according to claim 12, wherein said disorder of control of autonomic function is selected from the group consisting of essential hypertension and sleep disorders.

### Claim 17 (depends on 11)

The method, according to claim 11, wherein said individual is a human.

### Claim 18 (depends on 11)

The method, according to claim 11, wherein R4, R5, and R6 are, independently, selected from the group consisting of halo, amino, mono- and dialkylamino, and lower alkyloxy.

### Claim 19 (depends on 11)

The method, according to claim 11, wherein R4 is methoxy, R5 is amino or methylamino, and R6 is chloro, in the 2-, 4-, and 5-position of the phenyl ring, respectively.

### Claim 20 (depends on 11)

The method, according to claim 11, wherein said compound is selected from the group consisting of:
19
where IIIa and IIIb are mirror images of each other (enantiomers), and where L is defined as shown in Formula (II):
20
where n=1 to 4, X is a direct bond and Y is hydrogen, lower alkyl, or substituted aryl.

### Claim 21 (depends on 11)

The method, according to claim 11, wherein R1═OCH3; R2═H; X═O or N (if X═N, then R3═H); R4, R5, and R6 are methoxy, amino, and chlorine at the 2, 4, and 5-position of the phenyl ring, respectively.

### Claim 22 (depends on 11)

The method, according to claim 11, wherein both asymmetric centers are in the cis-configuration.
